drugset
drugset / Press release

Scandion Oncology announce topline results from part 2 of the CORIST phase II trial

2022-09-30 · Scandion Oncology A/S · original scandiononcology.com ↗

EMIDURDAR · results

Data from part 2 of the trial confirm the safety and tolerability of SCO-101. The trial will continue with part 3 exploring an optimized dosing schedule, aiming to utilize the full potential of SCO-101 in this indication and combination.

The release as fetched from its publisher. scandiononcology.com ↗